Connect Biopharma HldgsCNTB
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 17 institutions reported holding Connect Biopharma Hldgs Ltd. (CNTB) in their 13F filings, up 4 from Q1 2025. 6 opened new positions and 1 sold out. The largest holders were BML Capital Management, LLC ($1.8M), Choreo, LLC ($158K) and Renaissance Technologies ($141K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Connect Biopharma Hldgs Ltd.
- CUSIP
- 207523101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $220K |
| Exits | 1 | $148K |
All 13F filers, Q1 2025 → Q2 2025: 251,036 shares bought and 553,958 shares sold, net −302,922 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| BML Capital Management, LLC | 1.37% | Reduce -13.0% | 1,821,558 | $1.8M |
| Choreo, LLC | 0.00% | No change | 160,867 | $158K |
| Renaissance Technologies | 0.00% | Add +25.2% | 143,700 | $141K |
| AlphaCore Capital LLC | 0.00% | New | 80,000 | $78K |
| Citadel Advisors | 0.00% | New | 61,992 | $62K |
| Koa Wealth Management, LLC | 0.04% | New | 49,600 | $49K |
| Royal Bank of Canada | 0.00% | No change | 40,400 | $40K |
| XTX Topco Ltd | 0.00% | New | 28,862 | $29K |
| Geode Capital Management, LLC | 0.00% | Reduce -16.6% | 23,320 | $23K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 20,000 | $20K |
| ADAR1 Capital Management, LLC | 0.00% | No change | 10,300 | $10K |
| Rhumbline Advisers | 0.00% | No change | 2,370 | $2K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 1,582 | $2K |
| JPMorgan Chase & Co. | 0.00% | No change | 121 | $121 |
| Morgan Stanley | 0.00% | New | 100 | $98 |
| UBS Group AG | 0.00% | Reduce -99.5% | 42 | $41 |
| SBI Securities Co., Ltd. | 0.00% | No change | 6 | $6 |
"% of holder's portfolio" is CNTB's weight in each manager's 13F, not the share of Connect Biopharma Hldgs Ltd. the manager owns.